Evidence map›Paper›PMID 41432057›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Regulating Tumor Metabolic Reprogramming with Biomimetic Co-Delivery of Simvastatin and Kynureninase for Immunotherapy.

Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiaxin YinDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, 130012, China.
Shengcai YangKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Sciences, Jilin University, Changchun, 130012, China.
Zengguang LiuDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, 130012, China.
Songchen ZhaoDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, 130012, China.
Siyu SunKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Sciences, Jilin University, Changchun, 130012, China.
Ziling LiuDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, 130012, China.
Quanshun LiKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Sciences, Jilin University, Changchun, 130012, China.ORCID https://orcid.org/0000-0002-4115-7552

Funding

Development and Reform Commission of Jilin Province 2023C015Fundamental Research Funds of the Central Universities, China 2023-JCXK-25Fundamental Research Funds of the Central Universities, China 2024-JCXK-11National Key Research and Development Program of China 2024YFE0213800National Natural Science Foundation of China 32271319National Natural Science Foundation of China 52203168National Natural Science Foundation of China U24A20365Science and Technology Department of Jilin Province YDZJ202401328ZYTS
6 · The paper itself

Abstract

The metabolic reprogramming of immunosuppressive tumor microenvironment (ITME) greatly influences the anti-tumor immunity. Bioinformatic analysis demonstrates that indoleamine 2,3-dioxygenase 1 and 3-hydroxy-3-methylglutaryl coenzyme A reductase (key enzymes of kynurenine (Kyn) and cholesterol metabolism, respectively), are overexpressed in human colon adenocarcinoma tissues. Herein, biomimetic and pH/ROS dual-responsive nanoparticles (PTSK@CRM) loaded with simvastatin and kynureninase (KYNase) are prepared to regulate Kyn and cholesterol metabolism, thereby enhancing the immunotherapeutic efficacy of PD-1 antibody (αPD-1). The monodisperse spherical PTSK@CRM is stable at pH 7.4, while it can release simvastatin and KYNase under low pH and high H

Indexed as

Colonic NeoplasmsHydrolasesImmunotherapySimvastatinAnimalsBiomimeticsCell Line, TumorHumansMetabolic ReprogrammingMiceMice, Inbred BALB CNanoparticlesTumor MicroenvironmentHydrolaseskynureninaseSimvastatinimmunotherapykynureninasesimvastatintumor metabolic reprogramming

Identifiers

PMID41432057
PMCPMC12948188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.